Richmond, VANCT06914596Now EnrollingIRB Ready

Periodontitis (Stage 3) Clinical Trial in Richmond, VA

Access cutting-edge periodontitis (stage 3) treatment through this clinical trial at a research site in Richmond. Study-provided care at no cost to qualified participants.

Sponsored by McGuire Institute

Quick Self-Assessment

See if you qualify for this Richmond location

Preparing your pre-screening questions…

Expert Care in Richmond

Access periodontitis (stage 3) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related periodontitis (stage 3) treatment provided free

Apply for This Richmond Location

Check if you qualify for this periodontitis (stage 3) clinical trial in Richmond, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Richmond

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Richmond site if eligible
  4. 4Begin participation

About This Periodontitis (Stage 3) Study in Richmond

The goal of this clinical trial is to compare safety and to see if individuals with generalized stage III periodontitis that are given a periodontal hydrogel dressing on a wound healing after plaque and tartar have been removed from teeth have greater healing than individuals who are given no treatment after.

Sponsor: McGuire Institute

Who Can Participate

Inclusion Criteria

Subjects must meet all the following criteria to be entered into the study:
Subjects will have read, understood, and signed an institutional review board (IRB) approved Informed Consent Form (ICF).
Subjects 30 to 75 years of age.
Generalized Stage III periodontitis with at least 8 teeth having interproximal clinical attachment level of ≥3 mm and a probing pocket depth of ≥5 mm and ≤7mm, distributed between the mandible and the maxilla, with at least 2 qualifying interproximal sites in each arch. Localized and not more than 6 sites with a PD of 8 mm is acceptable as long as the tooth with 8 mm pocket depth is not clinically diagnosed as hopeless tooth with suppuration or mobility Grade 3 or greater.5-7
Subjects have a minimum of 24 natural teeth with a minimum of 2 natural teeth per quadrant excluding third molars.
All supragingival accretions can be removed from below the height of contour of the tooth crown to allow for a comprehensive periodontal evaluation and accurate intraoral digital scan of both arches at screening.
Subjects agree to refrain from use of oral rinses or dentifrice with known antibacterial properties (e.g., Peridex®, Listerine®, Colgate Total®, Crest Pro-Health®, etc.).
Subjects agree to refrain from use of electric flossers or irrigation devices for the duration of the study.
Subjects can provide self-care (oral hygiene) without disabilities requiring assistance with daily oral hygiene measures.
Subjects are able and willing to follow study procedures and instructions.

Exclusion Criteria

Subjects who meet the above inclusion criteria will be eligible for the study, unless they present with any of the following:
Periodontal surgery, implant placement or SRP within 12 months prior to screening or a cleaning/prophylaxis three months prior to screening.
Presence of fixed or removable (e.g. Invisalign) orthodontic appliances.
Subject with an underlying medical condition which requires antibiotic prophylaxis prior to dental treatment.
Subjects with vesiculobullous processes or other similar chronic oral lesions / conditions resulting in gingival irritation, discomfort/pain, or erosions.
Subjects with soft or hard tissue tumor(s) of oral cavity.
Use of any smoked substances such as tobacco / cannabis including cigarettes, vape, cigars, or use of smokeless tobacco 30 days prior to screening and throughout the study.
Uncontrolled medical conditions (e.g., diabetes mellitus, hypertension, cancer).
Subjects who are lactating or pregnant or planning to become pregnant through their projected study duration.
Subjects taking medications known to affect gingival conditions. (e.g., hyperplasia).
Regular, prolonged use of oral antimicrobial rinses 30 days prior to screening or continued anticipated use through their projected study duration.
Use of systemic antibiotics 30 days prior to screening or anticipated during the trial period.
Subjects taking corticosteroids on a regular basis one week prior to baseline examination and throughout the duration of the study, including oral inhalers.
Subjects taking non-steroidal anti-inflammatory (NSAIDS) or other pain medication on a daily basis for more than 3 consecutive days beginning one week prior to the baseline examination and throughout the duration of the study. Subjects are allowed to take 81 mg/day aspirin and may use oral pain medication if needed in the first 48- hours post-SRP period.
Subjects taking anticoagulant medications such as warfarin or Plavix or Eliquis.
Subjects participating in other clinical studies involving therapeutic intervention (either medical or dental) within 30 days of Screening.
Subjects that are known to be hypersensitive to chlorhexidine gluconate, glycerin, polyvinyl alcohol or ethylene vinyl acetate.
Subjects, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Richmond?

Yes, this clinical trial (NCT06914596) has an active research site in Richmond, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Periodontitis (Stage 3) Treatment Options in Richmond, VA

If you're searching for periodontitis (stage 3) treatment options in Richmond, VA, this clinical trial (NCT06914596) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Richmond research site is actively enrolling participants for this clinical trial. You'll receive care from experienced periodontitis (stage 3) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all periodontitis (stage 3) clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Richmond, VA

See all pulmonary embolism clinical trials recruiting in Richmond — not just this study.

Browse Pulmonary Embolism Trials in Richmond →

Browse More Trials by Condition

Pulmonary Embolism TrialsAll Conditions →

Ready to Join in Richmond?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Richmond, VA